 Phase II will find out the effects, good andor bad, of ixazomib in combination with ibrutinib. In Phase II, patients will be separated into 2 groups, patients who have never received ibrutinib and patients who have received ibrutinib. This study is designed to examine the effectiveness of this drug in treating patients with MCL. 